This phase II trial is testing the safety of an immunotherapy treatment in infants with newly diagnosed Acute Lymphoblastic Leukaemia (ALL).
This trial is treating patients with Acute Lymphoblastic Leukaemia (ALL).
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia
Other Non-Commercial Sponsor
Princess Máxima Center for Pediatric Oncology
Recruiting Hospitals Read More